NLRP3 sparks the Greek fire in the war against lipid‐related diseases

• Published in: Obesity reviews Vol. 21; no. 9; pp. e13045 - n/a
• Main Authors: Jiang, Shuai, Xiao, Haoxiang, Wu, Zhen, Yang, Zhi, Ding, Baoping, Jin, Zhenxiao, Yang, Yang
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.09.2020
• Subjects: Arteriosclerosis; Atherosclerosis; Chemical compounds; Diabetes mellitus (non-insulin dependent); Domains; Epidemics; Inflammasomes; Leucine; Lipids; lipid‐related diseases; Liver diseases; Metabolism; NLRP3 inflammasome; Nucleotides; Obesity; Oligomerization; Pharmacology; Pyrin protein; Regulatory mechanisms (biology); type 2 diabetes; atherosclerosis; lipid-related diseases; liver diseases; type 2 diabetes; NLRP3 inflammasome; obesity
• ISSN: 1467-7881; 1467-789X
• DOI: 10.1111/obr.13045

Summary In recent years, the obesity rate worldwide has reached epidemic proportions and contributed to the growing prevalence of lipid‐related diseases. A strong link between inflammation and metabolism is becoming increasingly evident. Compelling evidence has indicated the activation of the nucleotide‐binding and oligomerization domain‐like receptor, leucine‐rich repeat and pyrin domain‐containing 3 (NLRP3) inflammasome, a cytoplasmic complex containing multiple proteins, in a variety of lipid‐related diseases including obesity, atherosclerosis, liver diseases, and type 2 diabetes. Recent studies have further clarified the regulatory mechanisms and the optional therapeutic agents that target NLRP3 inflammasomes. In this study, we review the recent progress in the research on NLRP3 inflammasomes and discuss their implications for a better understanding of inflammation in lipid‐related disease and the prospects of targeting the NLRP3 inflammasome for therapeutic intervention.